

# Jeffrey H Lipton

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/1144974/jeffrey-h-lipton-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

111  
papers

1,347  
citations

18  
h-index

34  
g-index

123  
ext. papers

1,779  
ext. citations

3.6  
avg, IF

4.69  
L-index

#	Paper	IF	Citations
111	BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. <i>Cancer Cell</i> , <b>2014</b> , 26, 428-442	24.3	233
110	Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , <b>2016</b> , 17, 612-21	21.7	164
109	Treatment-free remission with first- and second-generation tyrosine kinase inhibitors. <i>American Journal of Hematology</i> , <b>2019</b> , 94, 346-357	7.1	61
108	Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy. <i>Blood</i> , <b>2017</b> , 129, 38-47	2.2	59
107	Similar outcomes of cryopreserved allogeneic peripheral stem cell transplants (PBSCT) compared to fresh allografts. <i>Biology of Blood and Marrow Transplantation</i> , <b>2007</b> , 13, 1233-43	4.7	52
106	Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study. <i>Leukemia and Lymphoma</i> , <b>2020</b> , 61, 650-659	1.9	50
105	Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance. <i>Vascular Health and Risk Management</i> , <b>2017</b> , 13, 293-303	4.4	41
104	Current approach to the treatment of chronic myeloid leukaemia. <i>Leukemia Research</i> , <b>2017</b> , 55, 65-78	2.7	38
103	Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study. <i>British Journal of Haematology</i> , <b>2017</b> , 179, 781-789	4.5	36
102	Reduced-Intensity Conditioning and Dual T Lymphocyte Suppression with Antithymocyte Globulin and Post-Transplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplants for Hematological Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 2259-2264	4.7	36
101	Detection of donor cell derived acute myelogenous leukaemia in a patient transplanted for chronic myelogenous leukaemia using fluorescence in situ hybridization. <i>British Journal of Haematology</i> , <b>1996</b> , 93, 163-5	4.5	30
100	Validation of National Institutes of Health global scoring system for chronic graft-versus-host disease (GVHD) according to overall and GVHD-specific survival. <i>Biology of Blood and Marrow Transplantation</i> , <b>2014</b> , 20, 556-63	4.7	27
99	Ponatinib in the therapy of chronic myeloid leukemia. <i>Expert Review of Hematology</i> , <b>2016</b> , 9, 923-32	2.8	22
98	Efficacy of Cidofovir in Treatment of BK Virus-Induced Hemorrhagic Cystitis in Allogeneic Hematopoietic Cell Transplant Recipients. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 1901-1905	4.7	21
97	Incidence and Risk Factors for Nontuberculous Mycobacterial Infection after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 366-372	4.7	20
96	Cardiovascular Events After Exposure to Nilotinib in Chronic Myeloid Leukemia: Long-term Follow-up. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2017</b> , 17, 870-878.e1	2	20
95	Retinal toxicity of high-dose hydroxychloroquine in patients with chronic graft-versus-host disease. <i>Canadian Journal of Ophthalmology</i> , <b>2015</b> , 50, 442-50	1.4	19

94	Low rates of acute and chronic GVHD with ATG and PTCy in matched and mismatched unrelated donor peripheral blood stem cell transplants. <i>European Journal of Haematology</i> , <b>2019</b> , 102, 486-493	3.8	18
93	Ocular masquerade syndrome in lymphoid blast crisis of chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , <b>1995</b> , 20, 161-3	1.9	18
92	A comparison of long-term outcomes of donor lymphocyte infusions and tyrosine kinase inhibitors in patients with relapsed CML after allogeneic hematopoietic cell transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2014</b> , 14, 87-92	2	17
91	Pregnancy: part of life in chronic myelogenous leukemia. <i>Leukemia and Lymphoma</i> , <b>2017</b> , 58, 280-287	1.9	16
90	Reduction of severe acute graft-versus-host disease using a combination of pre transplant anti-thymocyte globulin and post-transplant cyclophosphamide in matched unrelated donor transplantation. <i>Bone Marrow Transplantation</i> , <b>2018</b> , 53, 361-365	4.4	16
89	Impaired T cell responsiveness to interleukin-6 in hematological patients with invasive aspergillosis. <i>PLoS ONE</i> , <b>2015</b> , 10, e0123171	3.7	16
88	A Randomized Phase II Trial of Dasatinib 100 Mg Vs Imatinib 400 Mg In Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): The S0325 Intergroup Trial. <i>Blood</i> , <b>2010</b> , 116, LBA-6-LBA-6 <sup>2.2</sup>		16
87	Successful treatment of refractory red cell aplasia after allogeneic hematopoietic cell transplantation with daratumumab. <i>European Journal of Haematology</i> , <b>2020</b> , 104, 145-147	3.8	16
86	Exome sequencing reveals DNMT3A and ASXL1 variants associate with progression of chronic myeloid leukemia after tyrosine kinase inhibitor therapy. <i>Leukemia Research</i> , <b>2017</b> , 59, 142-148	2.7	15
85	Dual T-cell depletion with ATG and PTCy for peripheral blood reduced intensity conditioning allo-HSCT results in very low rates of GVHD. <i>Bone Marrow Transplantation</i> , <b>2020</b> , 55, 1773-1783	4.4	14
84	Safety and Efficacy of Haploidentical Peripheral Blood Stem Cell Transplantation for Myeloid Malignancies Using Post-transplantation Cyclophosphamide and Anti-thymocyte Globulin as Graft-Host Disease Prophylaxis. <i>Clinical Hematology International</i> , <b>2019</b> , 1, 105-113	1.8	14
83	Incidence, risk factors, and long-term outcomes of sclerotic graft-versus-host disease after allogeneic hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2014</b> , 20, 1751-7	4.7	13
82	Myeloablative versus Reduced-Intensity Conditioning in Patients with Myeloid Malignancies: A Propensity Score-Matched Analysis. <i>Biology of Blood and Marrow Transplantation</i> , <b>2016</b> , 22, 2270-2275	4.7	11
81	Reduced intensity allogeneic stem cell transplant with anti-thymocyte globulin and post-transplant cyclophosphamide in acute myeloid leukemia. <i>European Journal of Haematology</i> , <b>2019</b> , 103, 510-518	3.8	10
80	Modified EBMT Pretransplant Risk Score Can Identify Favorable-risk Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for AML, Not Identified by the HCT-CI Score. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2015</b> , 15, e73-81	2	10
79	Pilot prospective study of Frailty and Functionality in routine clinical assessment in allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 60-69	4.4	10
78	Exercise before, during, and after Hospitalization for Allogeneic Hematological Stem Cell Transplant: A Feasibility Randomized Controlled Trial. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	9
77	Allogeneic stem cell transplantation for mantle cell lymphoma--does it deserve a better look?. <i>Leukemia and Lymphoma</i> , <b>2005</b> , 46, 217-23	1.9	9

76	Improved prognostic stratification power of CIBMTR risk score with the addition of absolute lymphocyte and eosinophil counts at the onset of chronic GVHD. <i>Annals of Hematology</i> , <b>2017</b> , 96, 805-813	3	8
75	Characteristics, treatment and outcomes of nontuberculous mycobacterial pulmonary disease after allogeneic haematopoietic stem cell transplant. <i>European Respiratory Journal</i> , <b>2018</b> , 51,	13.6	8
74	HMGCLL1 is a predictive biomarker for deep molecular response to imatinib therapy in chronic myeloid leukemia. <i>Leukemia</i> , <b>2019</b> , 33, 1439-1450	10.7	8
73	Mechanisms of Cardiovascular Toxicity of BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia. <i>Current Hematologic Malignancy Reports</i> , <b>2020</b> , 15, 20-30	4.4	7
72	Quality of life trajectories during the first year following hematopoietic cell transplantation: an inception cohort study. <i>Supportive Care in Cancer</i> , <b>2018</b> , 26, 2379-2386	3.9	7
71	Inclusion body myositis in a patient with chronic myeloid leukemia treated with dasatinib: a case report. <i>Journal of Medical Case Reports</i> , <b>2015</b> , 9, 214	1.2	7
70	Single nucleotide polymorphisms in apoptosis pathway are associated with response to imatinib therapy in chronic myeloid leukemia. <i>Journal of Translational Medicine</i> , <b>2016</b> , 14, 82	8.5	6
69	Allogeneic Hematopoietic Stem Cell Transplantations in Blastic Plasmacytoid Dendritic Cell Neoplasm in first complete remission: an effective therapy for a rare disease. <i>Leukemia and Lymphoma</i> , <b>2016</b> , 57, 1942-4	1.9	6
68	Reduced-intensity conditioning allogeneic transplant with dual T-cell depletion in myelofibrosis. <i>European Journal of Haematology</i> , <b>2019</b> , 103, 597-606	3.8	6
67	Imatinib-induced gastric antral vascular ectasia in a patient with chronic myeloid leukemia. <i>Clinical Case Reports (discontinued)</i> , <b>2014</b> , 2, 77-8	0.7	6
66	CNS demyelination after initiating the tyrosine kinase inhibitor imatinib: A report of two cases. <i>Multiple Sclerosis Journal</i> , <b>2020</b> , 26, 1121-1124	5	6
65	Clinical prevalence and outcome of cardiovascular events in the first 100 days postallogeneic hematopoietic stem cell transplant. <i>European Journal of Haematology</i> , <b>2021</b> , 106, 32-39	3.8	6
64	Fresh vs. frozen allogeneic peripheral blood stem cell grafts: A successful timely option. <i>American Journal of Hematology</i> , <b>2021</b> , 96, 179-187	7.1	6
63	Dasatinib-Associated Major Molecular Responses Are Rapidly Achieved in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Following Resistance, Suboptimal Response, or Intolerance on Imatinib.. <i>Blood</i> , <b>2008</b> , 112, 1095-1095	2.2	5
62	Cardiovascular events in chronic myeloid leukemia clinical trials. Is it time to reassess and report the events according to cardiology guidelines?. <i>Leukemia</i> , <b>2018</b> , 32, 2095-2104	10.7	5
61	Long-Term Incidence of Secondary Malignancies after Allogeneic Hematopoietic Cell Transplantation: A Single-Center Experience. <i>Biology of Blood and Marrow Transplantation</i> , <b>2017</b> , 23, 945-951	4.7	4
60	Emerging alternatives to tyrosine kinase inhibitors for treating chronic myeloid leukemia. <i>Expert Opinion on Emerging Drugs</i> , <b>2018</b> , 23, 51-62	3.7	4
59	My jamais vu in post allogeneic hematopoietic cell transplant: a review on secondary hemophagocytosis in adults. <i>Bone Marrow Transplantation</i> , <b>2020</b> , 55, 867-872	4.4	4

58	Distinctive clinical characteristics and favorable outcomes in patients with large granular lymphocytosis after allo-HCT: 12-year follow-up data. <i>European Journal of Haematology</i> , <b>2017</b> , 99, 160-168	3.8	3
57	The role of ponatinib in chronic myeloid leukemia in the era of treatment free remission. <i>Leukemia and Lymphoma</i> , <b>2019</b> , 60, 3099-3101	1.9	3
56	Post-transplant cyclophosphamide combined with anti-thymocyte globulin for graft-vs-host disease prophylaxis improves survival and lowers non-relapse mortality in older patients undergoing allogeneic hematopoietic cell transplantation. <i>Annals of Hematology</i> , <b>2020</b> , 99, 1377-1387	3	3
55	Fludarabine and busulfan plus low-dose TBI as reduced intensity conditioning in older patients undergoing allogeneic hematopoietic cell transplant for myeloid malignancies. <i>Annals of Hematology</i> , <b>2018</b> , 97, 1975-1985	3	3
54	The true value of second-generation TKIs as first-line therapy in chronic myeloid leukaemia. <i>Lancet Haematology</i> , <b>2019</b> , 6, e385-e386	14.6	3
53	Omacetaxine mepesuccinate for management of chronic myeloid leukemia. <i>Expert Opinion on Orphan Drugs</i> , <b>2013</b> , 1, 745-754	1.1	3
52	High incidence but low mortality of EBV-reactivation and PTLN after alloHCT using ATG and PTCy for GVHD prophylaxis. <i>Leukemia and Lymphoma</i> , <b>2020</b> , 61, 3198-3208	1.9	3
51	Optimal duration of imatinib treatment/deep molecular response for treatment-free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trial. <i>British Journal of Haematology</i> , <b>2021</b> , 193, 779-791	4.5	3
50	Peripheral neuropathy associated with imatinib therapy for chronic myeloid leukemia. <i>Blood Research</i> , <b>2018</b> , 53, 172-174	1.4	3
49	Management of Hyperleukocytosis in Acute Myelogenous Leukemia Using Hydroxyurea Rather Than Leukopheresis.. <i>Blood</i> , <b>2006</b> , 108, 2007-2007	2.2	2
48	Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Final Results from ENESTxtnd Study. <i>Blood</i> , <b>2015</b> , 126, 344-344	2.2	2
47	Treatment Outcomes in Chronic Myeloid Leukemia: Does One Size Fit All?. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2020</b> , 18, 1421-1428	7.3	2
46	Impact of CD34+ cell dose on reduced intensity conditioning regimen haploidentical hematopoietic stem cell transplantation. <i>European Journal of Haematology</i> , <b>2020</b> , 104, 36-45	3.8	2
45	Prognostic impact of the adverse molecular-genetic profile on long-term outcomes following allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 1908-1918	4.4	2
44	Post-Transplant Cyclophosphamide Combined with Anti-Thymocyte Globulin as Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Acta Haematologica</i> , <b>2021</b> , 144, 66-73	2.7	2
43	Association of Factors Influencing Selection of Upfront Hematopoietic Cell Transplantation versus Nontransplantation Therapies in Myelofibrosis. <i>Transplantation and Cellular Therapy</i> , <b>2021</b> , 27, 600.e1-600.e8		2
42	Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option.. <i>Blood Reviews</i> , <b>2022</b> , 100968	11.1	2
41	Progressive multifocal leukoencephalopathy due to John Cunningham (JC) virus following allogeneic haematopoietic cell transplantation. <i>Antiviral Therapy</i> , <b>2017</b> , 22, 721-725	1.6	1

40	Less Is More: Superior Graft-versus-Host Disease-Free/Relapse-Free Survival with Reduced-Intensity Conditioning and Dual T Cell Depletion in Acute Myelogenous Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 1511-1519	4.7	1
39	Outcomes of therapy-related acute lymphoblastic leukemia in adults after allogeneic stem cell transplantation. <i>European Journal of Haematology</i> , <b>2020</b> , 105, 24-29	3.8	1
38	Epstein-Barr virus associated post-transplant lymphoproliferative disorder mimicking acute graft versus host disease. <i>European Journal of Haematology</i> , <b>2019</b> , 103, 519-522	3.8	1
37	Ruxolitinib for the treatment of disease-related splenomegaly or symptoms in adult patients with myelofibrosis. <i>International Journal of Hematologic Oncology</i> , <b>2014</b> , 3, 335-342	1	1
36	Predictors of the Trajectory of Neurocognitive Functioning in the First Six Months after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , <b>2015</b> , 126, 3289-3289	2.2	1
35	Anti-thymocyte globulin and post-transplant cyclophosphamide predisposes to inferior outcome when using cryopreserved stem cell grafts. <i>European Journal of Haematology</i> , <b>2022</b> , 108, 61-72	3.8	1
34	Inferior outcomes with reduced intensity conditioning followed by allogeneic hematopoietic cell transplantation in fit individuals with acute lymphoblastic leukemia: a Canadian single-center study and a comparison to registry data. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 62, 2193-2201	1.9	1
33	Experience Using Anti-Thymocyte Globulin With Post-Transplantation Cyclophosphamide for Graft-Versus-Host Disease Prophylaxis in Peripheral Blood Haploidentical Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , <b>2021</b> , 27, 428.e1-428.e9		1
32	A Pilot Randomized Controlled Trial of Adjuvanted Versus Nonadjuvanted Influenza Vaccine in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients. <i>Open Forum Infectious Diseases</i> , <b>2016</b> , 3,	1	1
31	Comorbidity profile of adult survivors at 20 years following allogeneic hematopoietic cell transplantation. <i>European Journal of Haematology</i> , <b>2021</b> , 106, 241-249	3.8	1
30	Effect of donor age and kinship on outcomes in haplo-identical stem cell transplantation may be modulated by GVHD prophylaxis strategies. <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 689-691	4.4	1
29	Prolactin, a potential biomarker for chronic GVHD activity. <i>European Journal of Haematology</i> , <b>2021</b> , 106, 158-164	3.8	1
28	Canadian chronic myeloid leukemia outcomes post-transplant in the tyrosine kinase inhibitor era. <i>Leukemia Research</i> , <b>2018</b> , 73, 67-75	2.7	1
27	Early prediction of stable MR by depth of molecular response at 6 months in patients with chronic myeloid leukemia treated with frontline imatinib. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 1-8	1.9	1
26	Therapeutic efficacy of azathioprine in addition to prednisone-based regimens as first-line chronic graft-versus-host disease treatment. <i>Bone Marrow Transplantation</i> , <b>2018</b> , 53, 334-338	4.4	0
25	Pretransplant bone marrow cellularity and blood count recovery are not associated with relapse or survival risk following allogeneic stem cell transplant for AML in CR. <i>European Journal of Haematology</i> , <b>2021</b> , 107, 354-363	3.8	0
24	Effect of pre-transplant JAK1/2 inhibitors and CD34 dose on transplant outcomes in myelofibrosis. <i>European Journal of Haematology</i> , <b>2021</b> , 107, 517-528	3.8	0
23	Chronic myeloid leukemia in solid organ transplant patients: a case series. <i>International Journal of Hematology</i> , <b>2021</b> , 113, 214-218	2.3	0



22	Subcutaneous immunoglobulin in allogeneic hematopoietic cell transplant patients: A prospective study of feasibility, safety, and healthcare resource use. <i>Hematology/Oncology and Stem Cell Therapy</i> , <b>2021</b> , 14, 302-310	2.7	o
21	Lower dose of ATG combined with post-transplant cyclophosphamide for HLA matched RIC alloHCT is associated with effective control of GVHD and less viral infections. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 1-11	1.9	o
20	Reply to letter to the editor. <i>Leukemia and Lymphoma</i> , <b>2017</b> , 58, 1273-1274	1.9	
19	Update on the management of chronic myeloid leukemia: current best practice and future directions. <i>Expert Opinion on Orphan Drugs</i> , <b>2019</b> , 7, 157-169	1.1	
18	Resolution of celiac disease, IgA deficiency and platelet refractoriness after allogeneic bone marrow transplantation for acute leukemia. <i>Haematologica</i> , <b>2019</b> , 104, e121-e123	6.6	
17	Management of Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Accelerated or Blastic Phase. <i>Drugs and Aging</i> , <b>2016</b> , 33, 335-45	4.7	
16	Disseminated soft tissue infection and sepsis with <i>Stenotrophomonas maltophilia</i> in a bone marrow transplant patient. <i>Canadian Journal of Infectious Diseases &amp; Medical Microbiology</i> , <b>1996</b> , 7, 383-5		
15	Optimal Duration of Imatinib Treatment / Deep Molecular Response for Treatment-Free Remission after Imatinib Discontinuation from a Canadian Tyrosine Kinase Inhibitor Discontinuation Trial. <i>Blood</i> , <b>2020</b> , 136, 54-55	2.2	
14	Genotypic and Phenotypic Spectrum of Dyskeratosis Congenita: Results from the Canadian Inherited Marrow Failure Registry. <i>Blood</i> , <b>2020</b> , 136, 8-9	2.2	
13	Largest Single Center Experience Using Dual T-Cell Depletion with ATG and Ptcy for Gvhd Prophylaxis in Peripheral Blood RIC Allo-HSCT. <i>Blood</i> , <b>2019</b> , 134, 3344-3344	2.2	
12	The 17-Gene Leukemic Stemess Score Can Predict Treatment Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia. <i>Blood</i> , <b>2019</b> , 134, 3299-3299	2.2	
11	Reduced Intensity Conditioning and Dual T-Cell Modulation Improves Gvhd Free, Relapse Free Survival in AML Patients Compared with Myeloablative Conditioning. <i>Blood</i> , <b>2019</b> , 134, 4590-4590	2.2	
10	No Impact of Donor Age-Related Clonal Hematopoiesis (ARCH) Observed on Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation: Result from Bar-Coded Error Corrected Sequencing in 33 Gene Mutations on 372 Pairs of Donor and Recipient. <i>Blood</i> , <b>2019</b> , 134, 4514-4514	2.2	
9	Propensity Score Matching Analysis Comparing Azathioprine Plus Prednisone Vs Prednisone Alone Regimens As First-Line Treatment in Chronic Graft-Versus-Host Disease. <i>Blood</i> , <b>2015</b> , 126, 3126-3126	2.2	
8	Analysis of Impact of Comorbidities Constituting the HCT-CI Score on the Outcome of Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia. <i>Blood</i> , <b>2015</b> , 126, 3201-3201	2.2	
7	Extramedullary Disease at Diagnosis of Acute Myeloid Leukemia Does Not Influence Outcome of Patients Undergoing Allogeneic Hematopoietic Cell Transplant in First Complete Remission. <i>Blood</i> , <b>2015</b> , 126, 2020-2020	2.2	
6	Whole Exome Sequencing Reveals the Landscape of Clonal Evolution from MDS to AML Progression. <i>Blood</i> , <b>2015</b> , 126, 2596-2596	2.2	
5	Predictors of Response Duration and Survival with Second-Line Bosutinib Therapy in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML) Resistant or Intolerant to Prior Imatinib. <i>Blood</i> , <b>2015</b> , 126, 4041-4041	2.2	

4	Donor Type, Chronic Gvhd Subtype , and the Severity of Chronic Gvhd at the Time of Initiation of Chronic Gvhd Treatment Affect Failure-Free Survival in the Patients with Chronic Gvhd. <i>Blood</i> , <b>2015</b> , 126, 3139-3139	2.2
3	Moderate-severe grade of chronic graft versus host disease and younger age (less than 45 years old) are risk factors for avascular necrosis in adult patients undergoing allogeneic hematopoietic cell transplantation. <i>Annals of Hematology</i> , <b>2021</b> , 100, 1311-1319	3
2	Refined hepatic grading system in chronic graft-versus-host disease improves prognostic risk stratification of long-term outcomes. <i>European Journal of Haematology</i> , <b>2021</b> , 106, 508-519	3.8
1	Making the case for the case report - informing physicians of intracranial hypertension as an adverse event in tyrosine kinase inhibitor treated chronic myeloid leukemia patients.. <i>Leukemia and Lymphoma</i> , <b>2022</b> , 1-2	1.9